Lipid F10T5
DC60840
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →| CAS No. | Not available |
| Chemical Name | Lipid MK16 |
| Synonyms | Lipid-MK16, MK 16, MK-16, MK16 BL |
| SMILES | CC(OCCCCCC)OCCCCCCN(CCCCCCOC(C)OCCCCCC)CCCCCCNC(CC[C@H]1CC[C@@](C2=CC(F)=CC=C2F)(S(C3=CC=C(Cl)C=C3)(=O)=O)CC1)=O |
| Formula | C55H91ClF2N2O7S |
| M.Wt | 997.84 |
| Purity | ELSD-HPLC>95% |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Wang C, Xue Y, Markovic T, et al. Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system. Nature Materials. 2025;24:1653-1663. |
Literature-reported formulation composition
| Component | Reported molar ratio | Role |
|---|---|---|
| MK16 | 60 | Ionizable lipid |
| DOPE | 30 | Helper phospholipid |
| Cholesterol | 40 | Sterol |
| DMG-PEG2k | 0.75 | PEG lipid |
| Reported ratio sum | 130.75 | Original ratio retained |
Formulation weight calculator
The cited formulation and available component molecular weights are pre-filled. Enter the exact molecular weight for any substituted material before calculating.
The source reports a non-normalized molar ratio with a sum of 130.75. The calculator normalizes these ratios only for component-weight calculation.
| Component | Molecular weight (g/mol) | Literature molar ratio |
|---|---|---|
| MK16 | ||
| DOPE | ||
| Cholesterol | ||
| DMG-PEG2k |
Calculated component requirements
| Component | Normalized mol% | Amount (µmol) | Required weight (mg) |
|---|---|---|---|
| Total | 100.000% | — | — |
Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.
Literature-reported performance for the cited formulation
Literature-reported6.86Post-formulation characterization · TNS fluorescence fitSupplementary Figure 6d
Literature-reported137.0 ± 4.1 nmPost-formulation characterization · MK16 BLNPMain text p. 1656; Supplementary Figure 9a
Literature-reported84.8 ± 1.5%Post-formulation characterization · RiboGreen assayMain text p. 1656; Supplementary Figure 9b
Literature-reported+5.87 ± 1.98 mVPost-formulation characterization · MK16 BLNPSupplementary Figure 9 and source data
Literature-reported8.3-fold the MC3 LNP signal6 h after 0.5 mg/kg IV FLuc mRNA · Also 1.7-fold MK6E, 7.4-fold ALC-0315 and 6.5-fold SM-102 in the reported comparisonsFigure 3d,e; Supplementary Figure 8
Literature-reported15.3 ± 0.4% of summed organ fluorescence1 h after 0.5 mg/kg IV Alexa Fluor 647-labelled RNA · Fluorescence distribution, not percent injected doseMain text p. 1656; Supplementary Figure 10b
Additional reported findings
At 1 mg mRNA/kg, the reported GFP-positive fractions were 7.36 ± 0.78% of neurons, 9.71 ± 0.70% of astrocytes, 9.18 ± 0.80% of brain capillary endothelial cells and 2.85 ± 0.44% of microglia.
GFP mRNA; single IV administration; mouse brain; 12 h · Figure 3f,g and main text p. 1658MK16 BLNP-Pten mRNA reduced tumor growth, and 70% of treated mice survived beyond 120 days in the reported orthotopic U-118MG model.
Pten mRNA; 1 mg/kg tail-vein IV on days 10, 13 and 16; immunodeficient mice · Figure 6 and main text p. 1661At the reported 1 mg/kg IV dose, inflammatory markers were generally no higher than the MC3 comparator, most returned toward baseline by 24-48 h, liver and kidney biomarkers remained within normal ranges, and histology showed no obvious abnormalities.
Mouse safety studies; study-specific formulation and dose · Supplementary Figures 14-17 and related main textLiterature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetWang C, Xue Y, Markovic T, et al. Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system. Nature Materials. 2025;24:1653-1663. DOI: 10.1038/s41563-024-02114-5
Structure: Figure 3c and Supplementary Scheme S2; exact pKa: Supplementary Figure 6d; optimized composition: main text p. 1654; particle properties and biodistribution: main text p. 1656 and Supplementary Figures 8-10; cellular delivery: main text pp. 1657-1658; disease-model findings: Figures 5-6.
Structure: Figure 3c and Supplementary Scheme S2; exact pKa: Supplementary Figure 6d; optimized composition: main text p. 1654; particle properties and biodistribution: main text p. 1656 and Supplementary Figures 8-10; cellular delivery: main text pp. 1657-1658; disease-model findings: Figures 5-6.